NCT00948220View on ClinicalTrials.gov

Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C

PHASE4CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

January 31, 2007

Study Completion Date

March 31, 2008

Conditions
Hepatitis C, ChronicLiver DiseasesVirus Diseases
Interventions
DRUG

peginterferon alfa-2a and ribavirin

standard antiviral therapy with peginterferon alfa-2a 180 µg/week and ribavirin 1000-1200 mg/d

Trial Locations (1)

89081

University Hospital Ulm, Ulm

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

University of Ulm

OTHER

NCT00948220 - Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C | Biotech Hunter | Biotech Hunter